Atrium Therapeutics (RNA)

• Market cap: $203M
• 1 day: 1.39%
• 5 days: 0.69%
• 1 month: -4.24%
• 3 months: -11.25%
• 6 months: -11.25%
• Year to date: -11.25%
• 1 year: -11.25%
• 5 years: -11.25%
• 10 years: -11.25%
• Sector: Healthcare
• Industry: Biotechnology

About: Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.

Employees: 391